On June 29, 2026, British oncology research groups published new guidance on streamlining specialty drug imports under the Medicines and Healthcare products Regulatory Agency (MHRA) personal use import regulations. For patients inside the UK's National Health Service (NHS), delays in securing advanced targeted therapies and monoclonal antibodies can significantly impact survival. Sourcing medicines like Keytruda and Herceptin internationally is a legal, safe alternative when local NHS supplies are restricted or experience supply-chain constraints.

At Onco Medicine, we have optimized our UK distribution routes to ensure clinical facilities and private addresses from London to Edinburgh receive verified cancer medicines under strict GDP compliance.

UK Sourcing & Regulatory Framework

• MHRA Personal Use Exemption: UK regulations permit individuals to import up to a 3-month supply of prescription medicines for personal or immediate family use, provided there is a valid prescription from a registered medical practitioner.
• Validated Cold-Chain Transit: Monoclonal antibodies are highly heat-sensitive. Onco Medicineutilizes active monitoring and thermal packaging to guarantee a strict 2–8°C window from airport dispatch to clinical administration.
• Traceable Quality Assurance: Every batch is supplied with an official Certificate of Analysis (COA) to guarantee chemical stability and molecule authenticity.

Patient care is our primary objective. By navigating the custom clearing processes and providing continuous telemetry records, Onco Medicine bridges the gap between global manufacturers and oncology clinics across the UK. We remain committed to helping patients access critical care without delay.